NPPA Revises Retail Prices Of 869 Formulations & Coronary Stents

NPPA has fixed retail prices of 869 formulations and coronary stents under Drugs Prices Control Order (DPCO)- 2013 based on price revision as per annual wholesale price index (WPI) of 1.88468 per cent increase.

1459
NPPA Price of drugs

Last Updated on February 4, 2021 by The Health Master

Mumbai: The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 869 formulations and coronary stents under Drugs Prices Control Order (DPCO)- 2013 based on price revision as per annual wholesale price index (WPI) of 1.88468 per cent increase.

The formulations include 5-aminosalicylic acid, abacavir (A) + lamivudine (B), acetazolamide, acetylsalicylic acid, acyclovir, allopurinol tablet, alprostadil, alteplase, amiodarone tablet, amlodipine tablet, amoxicillin capsule, amoxicillin (A) + clavulanic acid (B), amphotericin B (Lipid), anti-rabies immunoglobulin injection, artemether (A) + lumefantrine (B), ringer lactate injection 100 ml, 250 ml, 500 ml and 1000 ml among others.


Click below links to download the notifications

S.O.-1213-dt-25-03-2020-85[email protected]-1.88468-increase

S.O.-1214-dt-25-03-2020-13-items-Salicylic-acid-Cal-carbonate-Cond[email protected]-1.88468-increase

S.O.-1215-dt-25-03-2020-8-items-Glucose-Sod-Chlori[email protected]-1.88468-increase

S.O.-1216-dt-25-03-2020-16-items-Ringer-[email protected]-1.88468-increase

S.O.-1217-dt-25-03-2020-NPPA-has-fixed-revised-retail-prices-of-2-items-Stents-under-Drugs-Prices-Control-Order-2013


The ceiling prices of the formulations and coronary stents are applicable with effect from April 1, 2020.

The manufacturers of scheduled formulations selling above price higher than the ceiling price (plus goods and services taxes applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price as specified.

The manufacturers of specified scheduled formulations having MRP lower than the ceiling price specified (plus goods and services taxas applicable, if any), may revise the existing MRP of their formulations, on the basis of WPI @ 1.88468 per cent for year 2019 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.

The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price as specified.Bare metal coronary stents have been fixed at Rs. 8, 417 and Drug Eluting Stents (DES) including metallic DES and bioresorbable vascular scaffold (BVS)/biodegradable stents at Rs. 30, 647.

All the existing manufacturers/importers of coronary stents having MRP lower than the ceiling price specified (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of coronary stent, on the basis of WPI @ 1.88468 per cent for the year 2019 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013.

On February 14, 2017, NPPA announced for the first time cut in prices of coronary stents by up to 85% by capping them at Rs. 7,260 for bare metal ones and Rs. 29,600 for drug eluting variety.

The step was taken to fix a standardised specification of stent and its MRP to stop fleecing of patients. NPPA had written to all the chief secretaries to ensure compliance of stents price capping, its availability and uninterrupted cardiac care services.

The government brought in important reforms such as the National List of Essential Medicines (NLEM) in 2011 and also issued the Drug Price Control Order (DPCO) in 2013.


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading